// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

A Mechanistic Model Combines Macrophage Senescence And Cycles Of Metabolic Reprogramming To Explain Progression Of Multiple Sclerosis

Z. Bocskei - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Glial Cell Related Therapeutics

V. Miron - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Metabolomics aid Clinico-Pathophysiological Classification of CNS Inflammatory Demyelinating Diseases without Anti-AQP4 and Anti-MOG Antibodies

Tianrong Yeo - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Progressive Multiple Sclerosis Is Associated with Accelerated Inner and Outer Retinal Layer Atrophy

Elias S Sotirchos - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

An Exploratory Analysis of the Efficacy of Cladribine Tablets in Patients with RMS Stratified According to Age Above and below 45 Years in CLARITY

Kottil W Rammohan - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Cladribine

CLARITY: An Analysis of Severity and Frequency of Relapses in Patients with RMS Treated with Cladribine Tablets or Placebo

Gavin Giovannoni - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Cladribine

Durability of NEDA-3 Status in Patients with Relapsing Multiple Sclerosis Receiving Cladribine Tablets: CLARITY Extension

Gavin Giovannoni - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Multiple Sclerosis

Cladribine

Evaluating the Efficacy and Safety of 6-Week Extended Interval Dosing of Natalizumab Via a Prospective, Controlled, Randomized Phase 3b Study

Jeffrey A Cohen - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Natalizumab

GNbAC1 Shows Efficacy on MRI Measures of Neurodegeneration in Relapsing-Remitting MS Patients over 48 Weeks

Frederik Barkhof - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Temelimab

Long-Term Efficacy and Safety of Teriflunomide: An Analysis of Pooled Clinical Trials

Mark Freedman - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Teriflunomide

Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis

Stuart D Cook - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Cladribine

Clean-Surfaced, Faceted Gold Nanocrystals Promote Oligodendrocyte Differentiation, Induce a Redistribution of Mitochondria, and Promote Glycolysis

Ms. Joana M Tavares - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

N/A

MS-PML.Org, an e-Learning Resource for Physicians to Facilitate Early Recognition of PML in the Setting of MS: Analysis of Usage Data

Frederik Barkhof - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Childhood Obesity and Multiple Sclerosis Susceptibility: A Mendelian Randomization Study

Adil Harroud - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Multiple Sclerosis

N/A

Prudent Dietary Pattern Is Associated with a More Favorable Clinical Course in Early Multiple Sclerosis

Steve L Simpson - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Sclerosis

N/A

A Neurometabolic Profile of Secondary Progressive Multiple Sclerosis: The Relationship between Brain Metabolites and Clinical Disability

Nevin A John - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Multiple Sclerosis

Inositol

Influence of Magnetic Field Strength and Scanner Manufacturer on Magnetization Transfer Ratio Measures

Joyce Suhy - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Myelin Water Atlas: A Template for Myelin Distribution in the Brain

Mr. Hanwen Liu - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Ectodermal dysplasia-syndactyly syndrome

N/A

Pilot Assessment of Cervical Spinal Cord Myelin Content and Tissue Integrity in Neuromyelitis Optica Spectrum Disorder

Mr. Adam V Dvorak - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Neuromyelitis optica

N/A

An Interim Metagenomics Analysis of the International Multiple Sclerosis Microbiome Study (iMSMS)

Xiaoyuan Zhou - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Copyright © 2026. QuantiNova All rights reserved